Prognostic importance of transferrin receptor expression and correlation with K1-67 labelling indices in intracranial meningiomas

British Journal of Neurosurgery

Volumn 17, Issue 6, 2003, Pages 525-529

  Ucar T ^a   Gurer I ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Ki 67; Meningioma; Transferrin receptor (TfR)

Indexed keywords

KI 67 ANTIGEN; TRANSFERRIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACRANIAL TUMOR; LABELING INDEX; MALE; MALIGNANT TRANSFORMATION; MENINGIOMA; NEUROPATHOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SCHOOL CHILD; SEIZURE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MALE; MENINGIOMA; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RECEPTORS, TRANSFERRIN; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 1642538354     PISSN: 02688697     EISSN: None     Source Type: Journal    
DOI: 10.1080/02688690310001627759     Document Type: Article

References (45)

1. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma; late recurrence rate and factors, predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986;26:461-9.
2. May PL, Broome JC, Lawry J, Buxton R, Battersby RDE. The prediction of recurrence in meningiomas; a flow cytometric study of paraffin-embedded archival material. J Neurosurg 1989;71:347-51.
3. Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol 1998;29:1420-7.
4. Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, Inai K. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1 and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 2001;32:970-5.
5. Kakinuma K, Tanaka R, Onda K, Takahashi H. Proliferative potential of recurrent meningiomas as evaluated by labeling indices of BudR and Ki-67, tumour doubling time. Acta Neurochir (Wien) 1998;140:26-32.
6. Karampitopoulou E, Perentes E, Tolnay M, Probst A. Prognostic significance of MIB-1, p53 and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998;29:140-5.
7. Kyung GC, Takao H, Tadashi N, Murovic JA, Wilson CB. Prediction of tumor doubling time in recurrent meningiomas. J Neurosurg 1986;65:790-4.
8. Langford LA, Cooksley CS, DeMonte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol 1996;27:350-4.
9. Aisen P. Entry of iron into cells: a new role for the transferrin receptor in modulating iron release from transferrin. Ann Neurol 1992;32:62-8.
10. Connor JR, Brian SS, Paolo A, David AL, Peter LW. A quantitative analysis of isoferritins in selected regions of aged Parkinsonian and Alzheimer's diseased brains. J Neurochem 1995;65:717-24.
11. Huwyler J, Froidevaux S, Roux F, Eberle AN. Characterization of transferrin receptor in an immortalized cell line of rat brain endothelial cells, RBE4. J Recept Signal Transduct Res 1999;19:729-39.
12. Loeffler DA, Connor JR, Juneau PL, Snyder S, Kanaley L, DeMaggio AJ, Nguyen H, Brickman CM, LeWitt PA. Transferrin and iron in normal, Alzheimer's disease and Parkinson's disease brain regions. J Neurochem 1995;65:710-16.
13. Perl DP, Good PF. Comparative techniques for determining cellular iron distribution in brain tissues. Ann Neurol 1992;32:76-81.
14. Roelcke U, Leenders KL, von Ammon K, Radu EW, Vontobel P, Gunther I, Psylla M. Brain tumor iron uptake measured with positron emission tomography and 52Fe-citrate. J Neurooncol 1996;29:157-65.
15. Connor JR, Fine RE. Development of transferrin positive oligodendrocytes in the rat central nervous system. J Neurosci Res 1987;17:51-9.
16. Hill JM, Ruff MR, Weber RJ, Pert CB. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Neurobiology 1985;82:4553-7.
17. Hulet SW, Hess EJ, Debinski W, Arosio P, Bruce K, Powers S, Connor JR. Characterization and distribution of ferritin binding sites in the adult mouse brain. J Neurochem 1999;72:868-74.
18. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier transferrin receptor. Metabolism 1987;36:892-5.
19. Hall WA, Merrill MJ, Walbridge S, Youle RJ. Epidermal growth factor receptors on ependymomas and other brain tumors. J Neurosurg 1990;72:641-6.
20. Colombatti M, Massimo B, Lorena DA, Massimo AG, Guiseppe T. Sensitivity of human glioma cells to cytotoxic heteroconjugates. Int J Cancer 1988;42:441-8.
21. Gatter KC, Brown G, Strowbridge I, Woolston RE, Mason DY. Transferrin receptors in human tissues; their distribution and possible clinical relevance. J Clin Pathol 1983;36:539-45.
22. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue; implications for brain tumor immunotherapy. J Neurosurg 1990;72:941-5.
23. Faulk PW, Bai LH, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet 1980;23:390-2.
24. Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, Van Eijk HG, Swaak AJ. Regulation of iron metabolism in the acute phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest 1998;28:52-7.
25. Tampanaru SA, Stefaneanu L, Thapar K, Kontogeorgos G, Sumi T, Kovacs K. Transferrin and transferrin receptor in human hypophysis and pituitary adenomas. Am J Pathol 1998;152:413-22.
26. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22-39.
27. Hall WA, Godal A, Juell S, Fodstad O. In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme. J Neurosurg 1992;76:838-44.
28. Prior R, Reifenberger G, Wechsler W. Transferrin receptor expression in tumours of the human nervous system: relation to tumour type grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 1990;416:491-6.
29. Wen DY, Hall WA, Conrad J, Godal A, Florenes VA, Fodstad O. In vitro and in vivo variation in transferrin receptor expression on human medulloblastoma cell line. Neurosurgery 1995;36:1158-63.
30. Hall WA. Transferrin receptor on glioblastoma multiforme (Letter). J Neurosurg 1991;74:313-14.
31. Sasaki K, Matsumura K, Tsuji T, Shinozzaki F, Takahashi M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer 1988;62:989-93.
32. Nakasu S, Nakajima M, Matsumura K, Nakasu Y, Handa J. Meningioma proliferating potential and clinicoradiological features. Neurosurgery 1995;37:1049-55.
33. Nakasu S, Nakasu Y, Nakajima M, Matsuda M, Handa J. Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg 1999;90:455-62.
34. Nakasu S, Nakasu Y, Matsuda M. Meningioma recurrence. (Letter) J Neurosurg 2000;92:897-98.
35. Hall WA. Targeted toxin therapy for malignant astrocytoma. Neurosurgery 2000;46:544-52.
36. Johnson VG, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield EH, Youle R. Improved tumor specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 1989;70:240-8.
37. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8.
38. Martell LA, Agrawal A, Ross DA, Muraszko KM. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 1993;15:1348-53.
39. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des 1999;1:443-51.
40. Zovickian J, Johnson VG, Youle RJ. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody ricin immunotoxin. J Neurosurg 1987;66:850-86.
41. Bello L, Jianping Z, Demetrios CN, Jon FS, Roberto MV, David AC, Rona SC, Peter MB. αvβ3 and αvβ5 integrin expression in meningiomas. Neurosurgery 2000;47:1185-95.
42. Lee CS, Redshaw A, Boag G. NM 23-H1 protein immunoreactivity in laryngeal carcinoma. Cancer 1996;77:2246-50.
43. Nagashima G, Aoyagi M, Wakimoto H, Tamaki M, Ohno K, Hirakawa K. Immunohistochemical detection of progesterone receptors and correlation with Ki-67 labeling indices in paraffin embedded sections of meningiomas. Neurosurgery 1995;37:478-82.
44. Nakasu S, Li DH, Okabe H, Nakajima M, Matsuda M. Significance of MIB-1 staining indices in meningiomas; comparison of two counting methods. Am J Surg Pathol 2001;25:472-8.
45. Takashi T, Yasuhiro O, Kengo M, Takashi O. Peritumoral brain edema in intracranial meningiomas: effects of radiological and histological factors. Neurosurgery 2001;49:1046-52.